We'll monitor your thyroid antibodies and adjust your treatment plan as needed throughout your weight loss journey
Clinical implications of the trial outcomes for weight management Across the STEP trials, onceweekly subcutaneous semaglutide 2.4 mg demonstrated mean weight loss of 14.9%17.4% at 68 weeks in participants without diabetes with the mean baseline weight of 100107 kg, 38 , 40 , 41 , 43 offering the potential for clinically relevant improvement for individuals with obesityrelated diseases
Our guide on when to resume semaglutide after surgery covers pre-surgical holding periods and post-operative restart protocols
The afternoon is usually when our blood sugar crashes
The risk of death from any cause was 20% lower in the semaglutide group than in the placebo group (227 vs
The medication does not have to be forever: some patients use it as a bridge while they build new habits, others stay on longer with regular medical review